Swiss Medtech Gondola on the rise

Please login or
register
11.12.2020
Gondola device

Since Gondola Medical Technologies one year ago received a research grant of Euro 2.5M from the EIC Accelerator of the European Commission, the Swiss Medtech tripled the number of its employees, launched a new version of its device used to improve walking and balance impairments of patients with neurological disorders for domestic use and is set to expand in Europe.

Late 2019 Gondola Medical Technologies received a research grant of Euro 2.5 million from Horizon 2020 (EIC Accelerator Grant) of the European Commission. A defining milestone that helped the Swiss Medtech boost its activities as a company. Its GONDOLA AMPS treatment is a non-invasive, no side effects therapy for neurological conditions that cause walking and balance impairments. It helps patients to regain independence, to move better, and live better. 

On the clinical research side, despite the Covid-19 impact, the Swiss Medtech has added new studies in its research pipeline: one in collaboration with Uniklinik Köln in Germany, the other with Lausanne University Hospital (CHUV) in Switzerland.  

A growing market potential
On the business front, the startup has also been very active. Besides the recent launch of version 3.0 of the GONDOLA device for domestic use, assuring an easier to use version and scalable volumes, Gondola has extended the use of its AMPS treatment from Parkinson’s disease to other neurological disorders such as stroke and cerebral palsy, but also to spinal stroke and other conditions. Since 2012, Gondola has been able to treat more than 3500 patients at its Specialized Centers.

In a strategic move for its future development as a Medtech company, Gondola moved its HQ from Ticino to Biopôle in Lausanne. “A top-notch science park, renowned in Switzerland and internationally, and we are proud to be part of its life science community,” explains José Manuel Feijóo, Gondola’s Chief Business Development Officer. Over the last year, the Gondola team grew from 5 to 17 employees, scaling its scientific research, marketing, and sales activities.

As the Chief Business Development Officer further explained to Startupticker.ch, the geographical expansion into new markets, namely Germany, France, and Spain, is well underway. Other markets like the United States will follow in the months to come.

(ES)

0Comments

Company profiles on startup.ch

Gondola Medical Technologies SA

rss